Patient-Reported Outcomes of Trastuzumab Deruxtecan Therapy vs Treatment of Physician's Choice in Patients With HER2+ MBC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial
Lancet Oncol 2024 May 01;25(5)614-625, T Fehm, F Cottone, K Dunton, F André, I Krop, YH Park, M De Laurentiis, Y Miyoshi, A Armstrong, MR Borrego, R Yerushalmi, FP Duhoux, T Takano, W Lu, A Egorov, SB KimFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.